SCHEMBL1389062

SCHEMBL1389062

CCCCCCCCCCCC1=NC(=Cc2[nH]c(-c3ccc[nH]3)cc2OCc2ccccc2)C=C1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.33
EZH2 Q15910 1/20 0.32
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7514355 1.00 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
SCHEMBL1388984 1.00 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
SCHEMBL1717405 1.00 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
SCHEMBL12632563 1.00 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
Hydrochloric Acid SCHEMBL7513256 0.99 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
Hydrochloric Acid SCHEMBL7513262 0.99 BCHE (0.33) BCHEEZH2HTR2CSLC6A4
SCHEMBL7525880 0.99 BCHE (0.32) BCHEEZH2
SCHEMBL7525881 0.99 BCHE (0.32) BCHEEZH2
SCHEMBL7526413 0.96 PTGER1 (0.31)
SCHEMBL7526409 0.96 PTGER1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-0686147-B1 NOVEL 2,2'-BI-1H-PYRROLE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY PHARMACIA ITALIA SPA (IT) 2002-09-25 EP claimed
EP-0866701-B1 SYNERGISTIC IMMUNOSUPPRESSANT COMPOSITION CONTAINING A 2,2'-BI-1H-PYRROLE COMPOUND PHARMACIA & UPJOHN SPA (IT) 2002-01-16 EP claimed
EP-0825983-B1 PROCESS FOR THE PREPARATION OF 2,2'-BIPYRROLYL-PYRROMETHENE (PRODIGIOSINS) DERIVATIVES PHARMACIA & UPJOHN SPA (IT) 2001-08-29 EP claimed
EP-0975338-A2 2,2'-BI-1H-PYRROLE DERIVATIVES USEFUL IN THE TREATMENT OF LEUKEMIA BROUGHT ON BY HTLV-I PHARMACIA & UPJOHN S.p.A. (IT) 2000-02-02 EP claimed
WO-1999029309-A2 2,2'-BI-1H-PYRROLE DERIVATIVES USEFUL IN THE TREATMENT OF LEUKEMIA BROUGHT ON BY HTLV-I PHARMACIA & UPJOHN S.P.A. (IT) 1999-06-17 WO claimed
EP-0866701-A1 SYNERGISTIC IMMUNOSUPPRESSANT COMPOSITION CONTAINING A 2,2'-BI-1H-PYRROLE COMPOUND PHARMACIA & UPJOHN S.p.A. (IT) 1998-09-30 EP claimed
WO-1998011894-A1 SYNERGISTIC IMMUNOSUPPRESSANT COMPOSITION CONTAINING A 2,2'-BI-1H-PYRROLE COMPOUND PHARMACIA & UPJOHN S.P.A. (IT) 1998-03-26 WO claimed
US-5691334-A IMMUNOMODULATORS FOR SKIN GRAFTS, AUTOIMMUNE AND FOR ORGAN TRANSPLANTS PHARMACIA & UPJOHN S.P.A. (IT) 1997-11-25 US claimed
JP-H08507090-A 1996-07-30 JP claimed
EP-0686147-A1 NOVEL 2,2'-BI-1H-PYRROLE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY PHARMACIA & UPJOHN S.p.A. (IT) 1995-12-13 EP claimed
WO-1995017381-A1 NOVEL 2,2'-BI-1H-PYRROLE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY PHARMACIA S.P.A. (IT) 1995-06-29 WO claimed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-20250333441-A1 POLYPEPTIDE INHIBITORS AND USES THEREOF NEURACLE SCIENCE CO., LTD. (KR) 2025-10-30 US disclosed
EP-4634194-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
EP-4634193-A1 SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
WO-1998011894-A1 SYNERGISTIC IMMUNOSUPPRESSANT COMPOSITION CONTAINING A 2,2'-BI-1H-PYRROLE COMPOUND PHARMACIA & UPJOHN S.P.A. (IT) 1998-03-26 WO disclosed
US-5691334-A IMMUNOMODULATORS FOR SKIN GRAFTS, AUTOIMMUNE AND FOR ORGAN TRANSPLANTS PHARMACIA & UPJOHN S.P.A. (IT) 1997-11-25 US disclosed
EP-0686147-A1 NOVEL 2,2'-BI-1H-PYRROLE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY PHARMACIA & UPJOHN S.p.A. (IT) 1995-12-13 EP disclosed
WO-1995017381-A1 NOVEL 2,2'-BI-1H-PYRROLE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY PHARMACIA S.P.A. (IT) 1995-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE TACR1, ACHE, TACR2 BCHE 8/4885EZH2 4248/4885HTR2C 390/4885
US-20250333441-A1 POLYPEPTIDE INHIBITORS AND USES THEREOF LRRC59, FAM20C, LRRFIP1 BCHE 3527/4885EZH2 4373/4885HTR2C 4668/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 BCHE 530/4885EZH2 4006/4885HTR2C 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.